Global Landscape of MASH Therapeutics: Mechanistic Diversification and Clinical Evolution

Abstract Background : Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease. While resmetirom and semaglutide recently gained approval, effective therapies for MASH-related compensated cirrhosis (F4) remain lacking. This study systematically characterizes the global MASH trial portfolio to outline developmental trends and guide future trial design. Method : We analyzed the Informa repository for interventional MASH trials registered through December 2025. Excluding observational studies, 893 trials were included. Trial metadata, mechanisms of action (MOAs), patient inclusion criteria, endpoints, and diagnostic modalities were extracted and independently verified. Findings : The US (n=337) and China (n=115) led global registrations. GLP-1 receptor agonists (82) and FXR agonists (72) dominated mechanistic exploration, though only 41% of Phase III trials completed. Notably, negative-outcome trials enrolled significantly more F4 patients than successful trials (36.4% vs. 17.8%; P=0.024). Post-2020, GLP-1 agonists superseded FXR agonists in pipeline dominance. We identified 38 mid-to-late-stage combination trials, four completing with positive outcomes. Cardiometabolic endpoint integration surged from ~65% (2010) to >90% (post-2023), alongside increased adoption of non-invasive biomarkers. Conclusion : The MASH therapeutic pipeline is pivoting toward systemic, multi-mechanistic combination strategies integrating cardiometabolic co-management and non-invasive precision diagnostics. These insights inform the rational design of next-generation therapeutics for advanced disease.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11457775/v1
Primary Topic
Liver Disease Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Global Landscape of MASH Therapeutics: Mechanistic Diversification and Clinical Evolution

Qingshang Li, Zhijun Bao, Jiayi Wei, Zirui Zhang et al.
Research Square
Liver Disease Diagnosis and Treatment
preprint

Global Landscape of MASH Therapeutics: Mechanistic Diversification and Clinical Evolution

Qingshang Li, Zhijun Bao, Jiayi Wei, Zirui Zhang, Jingjing Zhou, Dan Ye, Xiaona Hu, Yuanwen Chen
preprint en

Abstract

Abstract Background : Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease. While resmetirom and semaglutide recently gained approval, effective therapies for MASH-related compensated cirrhosis (F4) remain lacking. This study systematically characterizes the global MASH trial portfolio to outline developmental trends and guide future trial design. Method : We analyzed the Informa repository for interventional MASH trials registered through December 2025. Excluding observational studies, 893 trials were included. Trial metadata, mechanisms of action (MOAs), patient inclusion criteria, endpoints, and diagnostic modalities were extracted and independently verified. Findings : The US (n=337) and China (n=115) led global registrations. GLP-1 receptor agonists (82) and FXR agonists (72) dominated mechanistic exploration, though only 41% of Phase III trials completed. Notably, negative-outcome trials enrolled significantly more F4 patients than successful trials (36.4% vs. 17.8%; P=0.024). Post-2020, GLP-1 agonists superseded FXR agonists in pipeline dominance. We identified 38 mid-to-late-stage combination trials, four completing with positive outcomes. Cardiometabolic endpoint integration surged from ~65% (2010) to >90% (post-2023), alongside increased adoption of non-invasive biomarkers. Conclusion : The MASH therapeutic pipeline is pivoting toward systemic, multi-mechanistic combination strategies integrating cardiometabolic co-management and non-invasive precision diagnostics. These insights inform the rational design of next-generation therapeutics for advanced disease.

Research Square
Fudan University (CN), Huadong Hospital (CN)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon